Search Results - "Vogelzang, J."

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now by Bellmunt, Joaquin, Powles, Thomas, Vogelzang, Nicholas J

“…Highlights • Bladder cancer incidence and mortality have changed little over the past 20 years. • Immunotherapy offers improved efficacy and tolerability over…”
Get full text

Unaccompanied Minor Refugee Life Skills: Navigating the U.S. Food Landscape by Vogelzang, J

Get full text

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Sweeney, Christopher J, Chen, Yu-Hui, Carducci, Michael, Liu, Glenn, Jarrard, David F, Eisenberger, Mario, Wong, Yu-Ning, Hahn, Noah, Kohli, Manish, Cooney, Matthew M, Dreicer, Robert, Vogelzang, Nicholas J, Picus, Joel, Shevrin, Daniel, Hussain, Maha, Garcia, Jorge A, DiPaola, Robert S

“…In this trial, the addition of six cycles of docetaxel to androgen-deprivation therapy resulted in longer median progression-free and overall survival than…”
Get full text

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial by Kyriakopoulos, Christos E, Chen, Yu-Hui, Carducci, Michael A, Liu, Glenn, Jarrard, David F, Hahn, Noah M, Shevrin, Daniel H, Dreicer, Robert, Hussain, Maha, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R, Vogelzang, Nicholas J, Picus, Joel, Cooney, Matthew M, Garcia, Jorge A, DiPaola, Robert S, Sweeney, Christopher J

“…Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate…”
Get full text

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study by Abida, Wassim, Campbell, David, Patnaik, Akash, Shapiro, Jeremy D, Sautois, Brieuc, Vogelzang, Nicholas J, Voog, Eric G, Bryce, Alan H, McDermott, Ray, Ricci, Francesco, Rowe, Julie, Zhang, Jingsong, Piulats, Josep Maria, Fizazi, Karim, Merseburger, Axel S, Higano, Celestia S, Krieger, Laurence E, Ryan, Charles J, Feng, Felix Y, Simmons, Andrew D, Loehr, Andrea, Despain, Darrin, Dowson, Melanie, Green, Foad, Watkins, Simon P, Golsorkhi, Tony, Chowdhury, Simon

“…Genomic alterations in DNA damage repair (DDR) genes other than may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate…”
Get full text

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study by Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H, Di Simone, Christopher, Hsieh, James J, Pinto, Alvaro, Shaffer, David R, Girones Sarrio, Regina, Cohn, Allen Lee, Vogelzang, Nicholas J, Bilen, Mehmet Asim, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V, Perini, Rodolfo F, Kubiak, Peter, Okpara, Chinyere E, Smith, Alan D, Motzer, Robert J

“…Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during…”
Get full text

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma by Bellmunt, Joaquim, de Wit, Ronald, Vaughn, David J, Fradet, Yves, Lee, Jae-Lyun, Fong, Lawrence, Vogelzang, Nicholas J, Climent, Miguel A, Petrylak, Daniel P, Choueiri, Toni K, Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Culine, Stéphane, Sternberg, Cora N, Mai, Yabing, Poehlein, Christian H, Perini, Rodolfo F, Bajorin, Dean F

“…In a randomized trial involving 542 patients with relapsed urothelial cancer, treatment with pembrolizumab resulted in overall survival of more than 10 months,…”
Get full text

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial by Hoskin, Peter, Prof, Sartor, Oliver, Prof, O'Sullivan, Joe M, Prof, Johannessen, Dag Clement, MD, Helle, Svein I, MD, Logue, John, FRCR, Bottomley, David, FRCR, Nilsson, Sten, Prof, Vogelzang, Nicholas J, Prof, Fang, Fang, PhD, Wahba, Mona, MD, Aksnes, Anne-Kirsti, PhD, Parker, Christopher, MD

“…Summary Background Primary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 by KEVIN KELLY, William, HALABI, Susan, VOGELZANG, Nicholas J, SMALL, Eric J, CARDUCCI, Michael, GEORGE, Daniel, MAHONEY, John F, STADLER, Walter M, MORRIS, Michael, KANTOFF, Philip, PAUL MONK, J, KAPLAN, Ellen

“…A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in…”
Get full text

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial by Sartor, Oliver, Prof, Coleman, Robert, Prof, Nilsson, Sten, Prof, Heinrich, Daniel, MD, Helle, Svein I, MD, O'Sullivan, Joe M, Prof, Fosså, Sophie D, Prof, Chodacki, Aleš, MD, Wiechno, Paweł, MD, Logue, John, FRCR, Widmark, Anders, Prof, Johannessen, Dag Clement, MD, Hoskin, Peter, Prof, James, Nicholas D, Prof, Solberg, Arne, MD, Syndikus, Isabel, FRCR, Vogelzang, Nicholas J, Prof, O'Bryan-Tear, C Gillies, MRCP, Shan, Minghua, PhD, Bruland, Øyvind S, Prof, Parker, Christopher, MD

“…Summary Background Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride…”
Get full text

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma by Pal, Sumanta K, Sonpavde, Guru, Agarwal, Neeraj, Vogelzang, Nicholas J, Srinivas, Sandy, Haas, Naomi B, Signoretti, Sabina, McGregor, Bradley A, Jones, Jeremy, Lanman, Richard B, Banks, Kimberly C, Choueiri, Toni K

“…Abstract Background Treatment of metastatic renal cell carcinoma (mRCC) typically entails mechanistically distinct agents across the first- and second-line…”
Get full text

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial by Hutson, Thomas E, Prof, Lesovoy, Vladimir, Prof, Al-Shukri, Salman, Prof, Stus, Viktor P, Prof, Lipatov, Oleg N, Prof, Bair, Angel H, PhD, Rosbrook, Brad, MS, Chen, Connie, PharmD, Kim, Sinil, MD, Vogelzang, Nicholas J, Prof

“…Summary Background In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had…”
Get full text

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial by SMITH, David C, SMITH, Matthew R, VAISHAMPAYAN, Ulka N, HAAS, Naomi B, SPIRA, Alexander I, LARA, Primo N, LIN, Chia-Chi, SRINIVAS, Sandy, SELLA, Avishay, SCHÖFFSKI, Patrick, SCHEFFOLD, Christian, WEITZMAN, Aaron L, SWEENEY, Christopher, HUSSAIN, Maha, ELFIKY, Aymen A, LOGOTHETIS, Christopher, CORN, Paul G, VOGELZANG, Nicholas J, SMALL, Eric J, HARZSTARK, Andrea L, GORDON, Michael S

“…Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We…”
Get full text

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer by Vaughn, David J, Bellmunt, Joaquim, Fradet, Yves, Lee, Jae Lyun, Fong, Lawrence, Vogelzang, Nicholas J, Climent, Miguel A, Petrylak, Daniel P, Choueiri, Toni K, Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Culine, Stephane, Sternberg, Cora N, Mai, Yabing, Li, Haojie, Perini, Rodolfo F, Bajorin, Dean F, de Wit, Ronald

“…Purpose In the phase III KEYNOTE-045 study ( ClinicalTrials.gov identifier: NCT02256436), pembrolizumab significantly prolonged overall survival compared with…”
Get full text

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) by Grivas, P, Loriot, Y, Morales-Barrera, R, Teo, M Y, Zakharia, Y, Feyerabend, S, Vogelzang, N J, Grande, E, Adra, N, Alva, A, Necchi, A, Rodriguez-Vida, A, Gupta, S, Josephs, D H, Srinivas, S, Wride, K, Thomas, D, Simmons, A, Loehr, A, Dusek, R L, Nepert, D, Chowdhury, S

“…ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic…”
Get full text

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study by Fizazi, Karim, Prof Dr, Scher, Howard I, Prof, Molina, Arturo, MD, Logothetis, Christopher J, Prof, Chi, Kim N, MD, Jones, Robert J, PhD, Staffurth, John N, MD, North, Scott, MD, Vogelzang, Nicholas J, MD, Saad, Fred, Prof, Mainwaring, Paul, MD, Harland, Stephen, MD, Goodman, Oscar B, MD, Sternberg, Cora N, MD, Li, Jin Hui, PhD, Kheoh, Thian, PhD, Haqq, Christopher M, MD, de Bono, Johann S, Prof

“…Summary Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the…”
Get full text

Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods? by Luinstra, M, Rutgers, A W F, Dijkstra, H, Grasmeijer, F, Hagedoorn, P, Vogelzang, J M J, Frijlink, H W, de Boer, A H

“…Because of its rapid onset of action, pulmonary administration of levodopa is an interesting alternative to oral administration for the rescue treatment of…”
Get full text

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA by Agarwal, Neeraj, Pal, Sumanta K., Hahn, Andrew W., Nussenzveig, Roberto H., Pond, Gregory R., Gupta, Sumati V., Wang, Jue, Bilen, Mehmet A., Naik, Gurudatta, Ghatalia, Pooja, Hoimes, Christopher J., Gopalakrishnan, Dharmesh, Barata, Pedro C., Drakaki, Alexandra, Faltas, Bishoy M., Kiedrowski, Lesli A., Lanman, Richard B., Nagy, Rebecca J., Vogelzang, Nicholas J., Boucher, Kenneth M., Vaishampayan, Ulka N., Sonpavde, Guru, Grivas, Petros

“…BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue…”
Get full text

Docetaxel-based combination therapy for castration-resistant prostate cancer by Galsky, M.D., Vogelzang, N.J.

“…Once castration resistance is documented and secondary hormone therapy is ineffective, standard treatment of metastatic prostate cancer is docetaxel, with…”
Get full text

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) by Agarwal, Neeraj, Tangen, Catherine M, Hussain, Maha H A, Gupta, Shilpa, Plets, Melissa, Lara, Primo N, Harzstark, Andrea L, Twardowski, Przemyslaw W, Paller, Channing J, Zylla, Dylan, Zibelman, Matthew R, Levine, Ellis, Roth, Bruce J, Goldkorn, Amir, Vaena, Daniel A, Kohli, Manish, Crispino, Tony, Vogelzang, Nicholas J, Thompson, Jr, Ian M, Quinn, David I

“…Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to…”
Get full text